CICC: Initiate Hutchison China MediTech with "outperform" rating, target price of HK$13.4

According to the Zhutong Finance APP, Zhongjin released a research report stating that it has initiated coverage on And Pharmaceutica-B (02142.HK) for the first time, giving it an "outperform" rating with a target price of 13.4 Hong Kong dollars. At the same time, it is expected that the company's earnings per share for 2025 and 2026 will be 0.09 and 0.02 Chinese yuan respectively.